Aspire Private Capital’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Aspire Private Capital’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-10	Closed	-$1.16K	–	755
2023 Q3	$1.16K	Sell	10 -25	-71%	-$2.69K	﹤0.01%	594
2023 Q2	$3.6K	Hold	35	–	–	﹤0.01%	489
2023 Q1	$3.82K	Buy	35 +10	+40%	+$1.1K	﹤0.01%	475
2022 Q4	$2.85K	Hold	25	–	–	﹤0.01%	496
2022 Q3	$2K	Sell	25 -7,057	-100%	-$493K	﹤0.01%	540
2022 Q2	$565K	Buy	7,082 +158	+2%	+$15K	0.2%	64
2022 Q1	$728K	Buy	6,924 +671	+11%	+$65.4K	0.23%	52
2021 Q4	$674K	Buy	6,253 +423	+7%	+$46.1K	0.21%	63
2021 Q3	$639K	Sell	5,830 -183	-3%	-$19K	0.21%	56
2021 Q2	$563K	Buy	6,013 +1,766	+42%	+$163K	0.18%	71
2021 Q1	$391K	Buy	+4,247	New	+$358K	0.14%	77

Other funds holding HZNP

IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return

BTI

Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return

VWA

Valued Wealth Advisors Holladay, Utah $247M AUM 21.93% 1-Year Est. Return

FSWA

Financial Synergies Wealth Advisors Houston, Texas $1.18B AUM 31.41% 1-Year Est. Return

BCMLT

Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $567M AUM 16.01% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Aspire Private Capital's HZNP Position: Q4 2023 in Review

Aspire Private Capital sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 10 shares — an estimated $1.16K sold.

Aspire Private Capital first reported a position in HZNP in Q1 2021 and held it in 11 quarters. The position peaked at $728K in Q1 2022. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

Aspire Private Capital reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
Aspire Private Capital sold 10 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $1.16K.
Aspire Private Capital first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2021 and held it in 11 quarters.
Aspire Private Capital's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $728K in Q1 2022.
6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on Aspire Private Capital's 13F filing for Q4 2023, filed 1 Feb 2024.